2004
DOI: 10.1038/ni1144
|View full text |Cite
|
Sign up to set email alerts
|

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

Abstract: B and T lymphocyte attenuator (BTLA) provides an inhibitory signal to B and T cells. Previously, indirect observations suggested that B7x was a ligand for BTLA. Here we show that BTLA does not bind B7x; instead, we identify herpesvirus entry mediator (HVEM) as the unique BTLA ligand. BTLA bound the most membrane-distal cysteine-rich domain of HVEM, distinct from regions where the ligands LIGHT and lymphotoxin-alpha bound HVEM. HVEM induced BTLA tyrosine phosphorylation and association of the tyrosine phosphata… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

14
554
2
3

Year Published

2006
2006
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 552 publications
(580 citation statements)
references
References 34 publications
14
554
2
3
Order By: Relevance
“…Thus, HVEM-Ig might inhibit T cell proliferation through an indirect effect against APCs in addition to the direct effect against T cells. On the other hand, HVEM is also known to bind to BTLA and CD160 expressed on T cells (del Rio et al 2010) and to induce coinhibitory signal (Cai et al 2008;Sedy et al 2005), raising the possibility that HVEM-Ig might stimulate this coinhibitory signaling. However, BTLA was reported to induce cell death in T cells in some cases (Deppong et al 2008), but we did not detect any additional T cell death by HVEM-Ig treatment (Fig.4).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Thus, HVEM-Ig might inhibit T cell proliferation through an indirect effect against APCs in addition to the direct effect against T cells. On the other hand, HVEM is also known to bind to BTLA and CD160 expressed on T cells (del Rio et al 2010) and to induce coinhibitory signal (Cai et al 2008;Sedy et al 2005), raising the possibility that HVEM-Ig might stimulate this coinhibitory signaling. However, BTLA was reported to induce cell death in T cells in some cases (Deppong et al 2008), but we did not detect any additional T cell death by HVEM-Ig treatment (Fig.4).…”
Section: Discussionmentioning
confidence: 99%
“…HVEM, initially identified as a herpes virus receptor, regulates T cell proliferation positively or negatively depending on its ligands (Cai and Freeman 2009). HVEM binds to LIGHT, augmenting T cell proliferation and IFN-γ production (Harrop et al 1998;Tamada et al 2000), whereas its binding to BTLA and CD160 negatively regulates T cell proliferation (Cai et al 2008;Sedy et al 2005). ICOS also enhances T cell activation, although it seems to be more important for differentiation of activated T cells (McAdam et al 2000).…”
Section: Introductionmentioning
confidence: 99%
“…Our studies failed to show any efficacy of LIGHT in human T cell activation, even though it was highly expressed on recombinant AdV modified-monocytes and capable of binding anti-LIGHT as well as its known receptors. Recent evidence shows that in addition to acting as a receptor for LIGHT, HVEM can function as a ligand for the immunoreceptor tyrosine inhibitory motif-containing receptor, B and T lymphocyte attenuator (55,56). Thus, it is possible that HVEM-B and T lymphocyte attenuator interaction predominates during T cell activation resulting in minimal impact of HVEM signaling in T cells.…”
Section: Discussionmentioning
confidence: 99%
“…HVEM interacts with an inhibitory receptor, B and T lymphocyte attenuator (BTLA), an immunoglobulin (Ig) superfamily (Figure 2) [25,26], known to attenuate lymphocyte activation, and thus a candidate regulator for DC. This non-canonical engagement of HVEM-BTLA induces an inhibitory signaling cascade regulating T and B cell proliferation.…”
Section: Counter Regulatory Mechanism For Dc: the Hvem-btla Pathwaymentioning
confidence: 99%